
## **Case Vignette**

A 21-year-old female, presented in medical OPD with the complaints of decrease sleep, anxiety, heat intolerance, increase frequency of defecation and palpitations for the last 2 months. According to the patient she has lost 5 kgs of her weight over the period of a month.

On examination: pulse 120/min and BP 140/100 mmHg. Patient has a staring gaze and a midline swelling in the neck which moves with swallowing.

# Hyperthyroidism And Graves' Disease

Dr. Nida Anjum, MU-II, HFH



LECTURE CONTENT ANALYSIS		
CORE CONTENT	60%	
HORIZONTAL INTEGRATION	20%	
VERTICAL INTEGRATION	15%	
RESEARCH & ETHICAL ISSUES	5%	

## **Learning Objectives**

At the end of the lecture students should be able to:

- 1. Define hyperthyroidism and Graves' disease, elucidating their underlying pathophysiology.
- 2. Describe the clinical manifestations and signs of hyperthyroidism including Graves diseases.
- 3. Explain the laboratory investigations used in the diagnosis of hyperthyroidism.

## **Learning Objectives**

At the end of the lecture students should be able to:

- 4: Describe extrathyroidal manifestations of Graves' disease.
- 5: Describe the management options for hyperthyroidism.
- 6: Differentiate between hyperthyroidism and hypothyroidism.

#### **Definitions**

**Thyrotoxicosis:** clinical, physiological, and biochemical findings that result when tissues are exposed to excess thyroid hormone irrespective of the underlying etiology.

**Hyperthyroidism:** conditions in which hyperfunction of the thyroid gland leads to thyrotoxicosis.

## **Epidemiology**

- > 10 times more common in females than in males in the UK.
- Prevalence is approximately 2 % of the female population.
- Annual incidence is 3 cases per 1,000 females.

## Classification of the etiology of thyrotoxicosis

**Associated with Hyperthyroidism** 

**Excessive thyroid stimulation** 

Graves disease

TSH pituitary adenoma

Thyroid nodules with autonomous

**Toxic MNG** 

**function** 

Toxic solitary nodule

## Classification of the etiology of thyrotoxicosis

**Not Associated with Hyperthyroidism** 

**Thyroid inflammation** Postpartum, Sub-acute thyroiditis

Drug Induced thyroiditis

**Ectopic thyroid tissue** Strauma ovarii

Metastatic thyroid cancer

### Clinical Symptoms and signs of Thyrotoxicosis

#### **Symptoms**

- Weight loss, increased
- > Hyperactivity, Irritability, appetite
  - insomnia

- Increase stool frequency
- Heat intolerance, sweating
- Oligomenorrhea, loss of

**Fatigue** 

libido

#### **Symptoms of Graves' Disease**

Graves' disease is the most common cause of hyperthyroidism, which causes the following symptoms:



Rapid heartbeat (palpitations).




Increased appetite.



Weight loss.







Diarrhea and/or more frequent bowel movements.



### Clinical Symptoms and signs of Thyrotoxicosis

#### Signs

- Sinus tachycardia, Atrial fibrillation
- Fine tremors, Hyperreflexia
- Warm and moist skin
- Palmer erythema


- > Hair loss
- Muscle weakness
- Congestive heart failure
- Hypokalemic periodic paralysis

#### **Graves Disease**

- Autoimmune disorder, antibodies production against TSH receptors.
- Thyroid stimulating antibodies bind to TSH receptors, acts as analog.
- Figure 2. Genetic predisposition: CTLA-4, HLA- DR 3.
- More common in females.
- Association with other autoimmune disorders.



**ARCHOPACHY** 






**THYROID DERMOPATHY** 



**DIFFUSE GOITER** 

#### Disorder of the thyroid gland




Diagnostic test for Hyperthyroidism

## **Thyroid Function test**

Condition	TSH	T <sub>3</sub>	T4
Primary Hyperthyroidi sm	Undetectable	<b>↑</b>	<b>↑</b>
Subclinical Hyperthyroidi sm		Normal	Normal
Secondary Hyperthyroidi sm	Normal or ↑		<b>↑</b>


## **Thyroid Antibodies**

Condition	Anti-TPO	Antithyroglo bulin	TSH receptor
Graves Disease	70 to 80%	30 to 50 %	70 to 100 %



## **Thyroid Scan**

#### Thyroid function tests (TFTs)



Management of Hyperthyroidism

#### 1:Antithyroid drugs:

Carbimazole, Propylthiouracil

2: Radioactive Iodine

3: Thyroidectomy

## Complication of Hyperthyroidism

- **1: Thyroid storm:** A severe, potentially fatal, hypermetabolic condition triggered by an overabundance of thyroid hormones (THs) in individuals experiencing thyrotoxicosis.
- 2: **Risk factors:** untreated or undertreated thyrotoxicosis, Surgery, Infection, Radioactive iodine therapy
- **3: Clinical Features:** Tachycardia, Hyperthermia, Hypertension, Severe agitation, Confusion, and Loss of consciousness
- 4: Management: IV propranolol, Thionamide, Iodine Solution, Glucocorticoid.

#### RESEARCH

► Cureus. 2023 Jun 23;15(6):e40851. doi: <u>10.7759/cureus.40851</u> 🖸

#### COVID-Induced Hyperthyroidism in a 30-Year-Old Female: A Case Study

Benjamin Ilyaev <sup>1,™</sup>, Sabina N Muminiy <sup>2</sup>, Emmanuella Borukh <sup>3</sup>, Emmanuel Izrailov <sup>4</sup>, Yakubmiyer Musheyev <sup>5</sup>, Stella Ilyayeva <sup>6</sup>

Editors: Alexander Muacevic, John R Adler

► Author information ► Article notes ► Copyright and License information

PMCID: PMC10363334 PMID: <u>37489189</u>

### **ETHICS**

Ethical Issue	Key Concerns
Informed Consent and Education	Ensuring patients understand treatment options (e.g., antithyroid drugs, radioactive iodine, surgery) along with potential complications like hypothyroidism.
Patient Autonomy	Respecting patient decisions regarding treatment choices, especially when opting out of recommended therapies.
Risk of Overtreatment	Avoiding excessive suppression of thyroid function, which may lead to iatrogenic hypothyroidism.
Equity in Access to Care	Ensuring access to diagnostic tests (e.g., thyroid function tests) and treatment across different socioeconomic groups.
Management During Pregnancy	Ethical considerations when managing hyperthyroidism in pregnancy, ensuring fetal safety while treating maternal hyperthyroidism.
Research Ethics	Ensuring ethical conduct in research on new treatments, including clear communication of risks and benefits to participants.
Thyrotoxic Crisis (Thyroid Storm)	Ethical dilemmas in emergency settings, particularly when a patient lacks the capacity to consent to treatment.

